Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Birrer on Prevalence of Cervical Cancer in the United States

January 9th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the prevalence of cervical cancer in the United States.

Dr. Birrer on Challenges With Patient Demographics in Cervical Cancer

January 5th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the challenges associated with the patient demographics of cervical cancer.

Dr. Birrer on Patient Preferences for Cervical Cancer Treatment

December 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses patient preferences for cervical cancer treatment, as well as the demographics of this population.

CT-Planned, High-Dose-Rate Brachytherapy Effective in Cervical Cancer

December 28th 2016

The use of CT-planned high-dose-rate intracavitary brachytherapy demonstrated excellent local control and survival for patients with stage I/II cervical carcinoma, according to the results of a recent study published in Gynecologic Oncology.

Expedited Surgery Increases Mortality Risk in Endometrial Cancer

December 27th 2016

Patients with endometrial cancer who receive surgery in the first 2 weeks after diagnosis have worse survival outcomes, according to a study recently reported in the American Journal of Obstetrics and Gynecology.

Study Links NSAIDs to Increased Mortality in Endometrial Cancer

December 27th 2016

An association was found between the use of nonsteroidal anti-inflammatory drugs and endometrial cancer risk.

Dr. Klopp on Goals With IMRT in Gynecological Cancers

December 20th 2016

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the next steps to take with pelvic intensity-modulated radiation therapy for patients with gynecological cancers.

Dr. Zamarin on Novel Immunotherapy Approaches in Gynecologic Cancers

December 14th 2016

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the novel approaches with immunotherapy that he would like to explore in the future treatment of patients with gynecologic cancers.

Dr. Klopp on a Comparison of Standard Radiation to IMRT in Gynecologic Malignancies

December 14th 2016

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.

Dr. Birrer on the Need for Novel Treatment Options in Cervical Cancer

December 13th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the novel treatment options that could be explored in the future treatment of patients with cervical cancer.

Dr. Birrer on Remaining Challenges in Cervical Cancer

November 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the remaining challenges in treating patients with cervical cancer.

Levine Sheds Light on Precision Medicine in Gynecologic Malignancies

November 28th 2016

Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.

Dr. Levine on Recent Progress in Cervical Cancer

November 23rd 2016

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.

Birrer Assesses Current Challenges in Cervical Cancer

November 21st 2016

Oncologists continue to face several challenges when it comes to the prevention and treatment of cervical cancer, according to Michael Birrer, MD, PhD.

HPV-Vaccinated Patients Require Less Frequent Cervical Cancer Screening

November 17th 2016

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended, according to new findings released from the Harvard T.H. Chan School of Public Health.

Dr. Michael Birrer on Immunotherapy Potential in Cervical Cancer

November 16th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses recent advancements in cervical cancer.

More Than Half of Cervical Cancer Patients Not Receiving Recommended Treatment

November 8th 2016

Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.

Pembrolizumab Shows Promising Antitumor Activity in Cervical Cancer

September 30th 2016

Pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1–positive advanced cervical squamous cell cancer.

Study Shows Cervical Cancer Screening Reduces Mortality

September 29th 2016

Regular screening for cervical cancer was found to be associated with an overall mortality prevention rate of 83%.

Fewer GI, GU Toxicities With Postoperative Pelvic IMRT in Gynecologic Malignancies

September 29th 2016

Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.